Seattle Genetics, Inc. (NASDAQ:SGEN)
CAPS Rating:
A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
0
HornOCopia
(55.44)
Submitted: 1/22/2007 6:22:13 AM :
Start Price:
$7.03
SGEN Score:
+194.60
Cancer therapy pipeline...Genenthech's and other's interest.
Recs
1
saranv
(< 20)
Submitted: 1/17/2007 1:46:11 AM :
Start Price:
$7.25
SGEN Score:
+185.57
Based on existing data, Seattle Genetics Have promisisng pipeline and in addition genentech is sponsoring the research and development costs associated with SGN40 which is great news for the company.
Recs
0
JTODD04
(98.94)
Submitted: 12/21/2006 2:29:43 PM :
Start Price:
$5.62
SGEN Score:
-267.10
TMFBreakerCharly pick
Recs
1
vkowalczuk
(61.63)
Submitted: 10/18/2006 6:26:08 PM :
Start Price:
$5.10
SGEN Score:
+300.50
DNA research and production
Recs
1
lloydvon
(89.13)
Submitted: 8/29/2006 9:35:45 PM :
Start Price:
$4.48
SGEN Score:
+351.54
A very promising biotech company with large insider ownership makes this drug company a very comfortable pick in my portfolio.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 61 - 65 of 65 : « Previous 1 2 3 4